U.S. flag

An official website of the United States government

NM_001366385.1(CARD14):c.2503del (p.Arg835fs) AND multiple conditions

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 26, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003795293.2

Allele description [Variation Report for NM_001366385.1(CARD14):c.2503del (p.Arg835fs)]

NM_001366385.1(CARD14):c.2503del (p.Arg835fs)

Genes:
LOC126862662:MED14-independent group 3 enhancer GRCh37_chr17:78178385-78179584 [Gene]
SGSH:N-sulfoglucosamine sulfohydrolase [Gene - OMIM - HGNC]
CARD14:caspase recruitment domain family member 14 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_001366385.1(CARD14):c.2503del (p.Arg835fs)
HGVS:
  • NC_000017.11:g.80205139del
  • NG_008229.2:g.20194del
  • NG_032778.1:g.40148del
  • NG_087159.1:g.654del
  • NM_001366385.1:c.2503delMANE SELECT
  • NM_024110.4:c.2503del
  • NP_001353314.1:p.Arg835fs
  • NP_077015.2:p.Arg835fs
  • LRG_1330t1:c.2503del
  • LRG_1330:g.40148del
  • LRG_1330p1:p.Arg835fs
  • NC_000017.10:g.78178938del
  • NR_047566.2:n.2640del
Protein change:
R835fs
Molecular consequence:
  • NM_001366385.1:c.2503del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_024110.4:c.2503del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NR_047566.2:n.2640del - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Pityriasis rubra pilaris (PRP)
Synonyms:
Pityriasis rubra pilaris--familial type
Identifiers:
MONDO: MONDO:0100017; MedGen: C0032027; Orphanet: 2897; OMIM: 173200
Name:
Psoriasis 2
Identifiers:
MONDO: MONDO:0011269; MedGen: C1864497; OMIM: 602723

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV004579194Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Uncertain significance
(Jan 26, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004579194.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant has not been reported in the literature in individuals affected with CARD14-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg835Glyfs*7) in the CARD14 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in CARD14 cause disease.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024